Fatty Liver Disease - Pipeline Review, H1 2015
Fatty Liver Disease - Pipeline Review, H1 2015 is a new market research
publication announced by Reportstack. This report provides an overview of the Fatty Liver Disease’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
- The report provides a snapshot of the global therapeutic landscape of Fatty Liver Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fatty Liver Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fatty Liver Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
ACROVIS biostructures GmbH ChemoCentryx, Inc. Conatus Pharmaceuticals Inc. Daewoong Pharmaceutical Co., Ltd. Dr. Falk Pharma GmbH DURECT Corporation Galmed International Ltd. Generon (Shanghai) Corporation Ltd. Genovate Biotechnology Co., LTD. Gilead Sciences, Inc. Huons Co., Ltd. Kyorin Pharmaceutical Co., Ltd. Metabolic Solutions Development Company, LLC Novartis AG Protalix BioTherapeutics, Inc. Raptor Pharmaceuticals Corp. TCM Biotech International Corp Tobira Therapeutics, Inc. Verva Pharmaceuticals Limited Zafgen Inc.
This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
- The report provides a snapshot of the global therapeutic landscape of Fatty Liver Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fatty Liver Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fatty Liver Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
ACROVIS biostructures GmbH ChemoCentryx, Inc. Conatus Pharmaceuticals Inc. Daewoong Pharmaceutical Co., Ltd. Dr. Falk Pharma GmbH DURECT Corporation Galmed International Ltd. Generon (Shanghai) Corporation Ltd. Genovate Biotechnology Co., LTD. Gilead Sciences, Inc. Huons Co., Ltd. Kyorin Pharmaceutical Co., Ltd. Metabolic Solutions Development Company, LLC Novartis AG Protalix BioTherapeutics, Inc. Raptor Pharmaceuticals Corp. TCM Biotech International Corp Tobira Therapeutics, Inc. Verva Pharmaceuticals Limited Zafgen Inc.
To access
full report with TOC, please visit Fatty Liver Disease - Pipeline Review, H1 2015
About
Reportstack:
Reportstack
is one of the leading distributors of market research reports in the
world today. We host more than 200,000 research products from the world's top
publication houses. These publications are distributed amongst 12 top industry
verticals and 62 sub verticals, which are then further classified into 257
business categories and 5000 micro markets. The vast selection criterion
provides granular data from the length and breadth of all these industries
delivering Reportstack members with cutting edge research products to
facilitate strategic business decisions.
Contact:
Debora
White
Manager -
Marketing
Ph:
+1-888-789-6604
Reportstack
Market Research
posted by Reportstack @ 04:00
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home